369 related articles for article (PubMed ID: 16472864)
1. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
Judge SI; Bever CT
Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
[TBL] [Abstract][Full Text] [Related]
2. 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
Göbel K; Wedell JH; Herrmann AM; Wachsmuth L; Pankratz S; Bittner S; Budde T; Kleinschnitz C; Faber C; Wiendl H; Meuth SG
Exp Neurol; 2013 Oct; 248():62-71. PubMed ID: 23748135
[TBL] [Abstract][Full Text] [Related]
3. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release fampridine for multiple sclerosis.
Bever CT; Judge SI
Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
[TBL] [Abstract][Full Text] [Related]
5. Fampridine-SR for multiple sclerosis and spinal cord injury.
Hayes KC
Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation.
Espejo C; Montalban X
Clin Immunol; 2012 Jan; 142(1):84-92. PubMed ID: 21742559
[TBL] [Abstract][Full Text] [Related]
8. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
9. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
10. [Aminopyridines for symptomatic treatment of multiple sclerosis].
Jensen HB; Stenager E; Ravnborg MH
Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Properties of 4-Aminopyridine.
Dietrich M; Hartung HP; Albrecht P
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33653963
[TBL] [Abstract][Full Text] [Related]
12. 4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury.
McBride JM; Smith DT; Byrn SR; Borgens RB; Shi R
Neuroscience; 2007 Aug; 148(1):44-52. PubMed ID: 17629412
[TBL] [Abstract][Full Text] [Related]
13. Dalfampridine (Ampyra) for MS.
Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716
[No Abstract] [Full Text] [Related]
14. Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis.
Krishnan AV; Kiernan MC
Mult Scler; 2013 Apr; 19(4):385-91. PubMed ID: 23077091
[TBL] [Abstract][Full Text] [Related]
15. Oxyhemoglobin-induced suppression of voltage-dependent K+ channels in cerebral arteries by enhanced tyrosine kinase activity.
Ishiguro M; Morielli AD; Zvarova K; Tranmer BI; Penar PL; Wellman GC
Circ Res; 2006 Nov; 99(11):1252-60. PubMed ID: 17068294
[TBL] [Abstract][Full Text] [Related]
16. The current status of studies of aminopyridines in patients with multiple sclerosis.
Bever CT
Ann Neurol; 1994; 36 Suppl():S118-21. PubMed ID: 8017870
[TBL] [Abstract][Full Text] [Related]
17. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
18. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
Davis FA; Stefoski D; Rush J
Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
[TBL] [Abstract][Full Text] [Related]
19. Effects of various K+ channel blockers on spontaneous glycine release at rat spinal neurons.
Shoudai K; Nonaka K; Maeda M; Wang ZM; Jeong HJ; Higashi H; Murayama N; Akaike N
Brain Res; 2007 Jul; 1157():11-22. PubMed ID: 17555723
[TBL] [Abstract][Full Text] [Related]
20. Aminopyridines for symptomatic treatment in multiple sclerosis.
Solari A; Uitdehaag B; Giuliani G; Pucci E; Taus C
Cochrane Database Syst Rev; 2002; (4):CD001330. PubMed ID: 12804404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
